Yüksel H, Yüksel D, Demir E, Tanaç R, Kayaliodlu M
Department of Pediatric Allergy and Pneumatology, Ege University, Bornova-Izmir, Turkey.
Allergy Asthma Proc. 2000 Nov-Dec;21(6):361-5. doi: 10.2500/108854100778249114.
The aim of this study was to evaluate the effect of inhaled steroid therapy on the distribution of inhaled Tc-99m DTPA in asthmatic children. Twenty-one asthmatic children and 15 healthy controls were entered in this study. The distribution of radioaerosols was scored by using a modified standardized score system over both lungs and expressed as homogeneity score/patient. The baseline homogeneity score was calculated before the inhalation therapy of budesonide (400 micrograms/day) for six months. The homogeneity score was repeated at the end of the second and sixth months of therapy. Asthmatic symptom scores and peak-flow rate variability, which were observed to improve throughout the study, were also recorded. Although homogeneity scores of the controls demonstrated no abnormality, mean baseline homogeneity scores of asthmatics was significantly high, 1.7 +/- 0.4/patient, and decreased to 0.6 +/- 0.2 and 0.3 +/- 0.1/patient at the end of second and sixth months, respectively (p < 0.05). These results revealed significant improvement in the radioaerosol distribution after inhaled steroid therapy. It was concluded that the lack of homogeneity in the distribution of Tc99m-DTPA in the lung, as an indicator for ventilation defects, may be accepted as a useful, noninvasive tool to monitor the efficacy of the therapy with inhaled agents in childhood asthma.
本研究旨在评估吸入性类固醇疗法对哮喘患儿吸入的锝-99m二乙三胺五乙酸(Tc-99m DTPA)分布的影响。21名哮喘患儿和15名健康对照者纳入本研究。通过使用改良的标准化评分系统对双肺放射性气溶胶的分布进行评分,并以每个患者的均匀性评分表示。在吸入布地奈德(400微克/天)进行为期6个月的治疗前计算基线均匀性评分。在治疗的第二个月和第六个月末重复测量均匀性评分。还记录了哮喘症状评分和峰值流速变异性,在整个研究过程中观察到它们有所改善。尽管对照组的均匀性评分未显示异常,但哮喘患儿的平均基线均匀性评分显著较高,为1.7±0.4/患者,在第二个月末和第六个月末分别降至0.6±0.2/患者和0.3±0.1/患者(p<0.05)。这些结果表明吸入性类固醇治疗后放射性气溶胶分布有显著改善。得出的结论是,作为通气缺陷指标的肺内Tc99m-DTPA分布缺乏均匀性,可被视为监测儿童哮喘吸入药物治疗疗效的一种有用的非侵入性工具。